Back to all papers

Prognostic significance of artificial intelligence-quantified late gadolinium enhancement on cardiac magnetic resonance in hypertrophic cardiomyopathy.

September 1, 2026pubmed logopapers

Authors

Jeong YS,Park JI,Choi KU,Nam JH,Lee CH,Son JW,Kim U,Park JS,Kong E

Affiliations (3)

  • Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea.
  • Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea. [email protected].
  • Department of Nuclear Medicine, Yeungnam University Medical Center, Daegu, Korea.

Abstract

This study aimed to evaluate the prognostic value of artificial intelligence (AI)-based late gadolinium enhancement (LGE) quantification using cardiovascular magnetic resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM). We retrospectively analyzed 142 patients with HCM (mean age 58.5 ± 13.7 yr; 72.5% men) who underwent CMR at Yeungnam University Medical Center between 2015 and 2023. LGE was quantified using an AI-based segmentation algorithm with a 6-standard deviation method. Patients were stratified into a high LGE group (≥ 15%) and a low LGE group (< 15%). The primary outcome was a composite of cardiovascular death, including sudden cardiac death (SCD) and SCD-equivalent events. Over a median follow-up of 59 months, the high LGE group experienced a higher incidence of the primary outcome compared with the low LGE group (21.2% vs. 4.6%, p = 0.0067). After adjustment for age and left ventricular ejection fraction, a high AI-quantified LGE burden (≥ 15%) remained independently associated with the primary outcome (adjusted hazard ratio 4.67, 95% confidence interval 1.43-15.30, p = 0.011). Receiver operating characteristic analysis determined an optimal LGE cutoff of 8% for predicting the primary outcome (area under the curve 0.821). Patients with LGE ≥ 8% exhibited markedly increased rates of the primary outcome (18.2% vs. 0%, p < 0.001) and SCD/SCD-equivalent events (13.6% vs. 0%, p = 0.00074). AI-based quantitative assessment of LGE is an independent predictor of adverse cardiovascular outcomes in patients with HCM and may represent a clinically meaningful imaging biomarker for risk stratification.

Topics

Cardiomyopathy, HypertrophicContrast MediaArtificial IntelligenceGadoliniumMagnetic Resonance Imaging, CineJournal Article

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.